tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Panniculitis, Lupus Erythematosus D015435 1 associated lipids
Retrognathia D063173 1 associated lipids
Mediastinal Diseases D008477 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Fredericks S et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. 2006 Transplantation pmid:16969296
Peterson LB et al. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. 1998 Transplantation pmid:9448137
Keenan RJ et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. 1991 Transplantation pmid:1719668
Thomas J et al. The immunosuppressive action of FK506. In vitro induction of allogeneic unresponsiveness in human CTL precursors. 1990 Transplantation pmid:1689518
Marcos A et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. 2004 Transplantation pmid:15480160
Vathsala A et al. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. 1990 Transplantation pmid:1689520
Rolles K et al. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. 1999 Transplantation pmid:10551650
Pirsch JD Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. 1999 Transplantation pmid:10551653
Zoppo A et al. Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. 1999 Transplantation pmid:10551656
Bayer ND et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. 2010 Transplantation pmid:20724958
Furukawa H et al. Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs. 2000 Transplantation pmid:10670633
Mañez R et al. Fluconazole therapy in transplant recipients receiving FK506. 1994 Transplantation pmid:7515201
Jordan ML et al. Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. 2000 Transplantation pmid:10670637
Hirose R et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. 2000 Transplantation pmid:10670644
Naesens M et al. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. 2007 Transplantation pmid:17700162
Kato T et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. 2007 Transplantation pmid:17984834
Sindhi R et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. 2001 Transplantation pmid:11571449
Chaftari AM et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. 2012 Transplantation pmid:22814329
Jain A et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. 2000 Transplantation pmid:11087149
Tzakis AG et al. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. 2003 Transplantation pmid:12792506
Koenen HJ et al. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. 2003 Transplantation pmid:12792519
Egeland EJ et al. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. 2017 Transplantation pmid:28452920
Heilman RL et al. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal. 2012 Transplantation pmid:22067270
Hricik DE et al. Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. 2007 Transplantation pmid:17297401
Shao X et al. Tacrolimus-associated ischemic optic neuropathy and posterior reversible encephalopathy syndrome after small bowel transplantation. 2012 Transplantation pmid:23128973
Nicolai S and Bunyavanich S Hypersensitivity reaction to intravenous but not oral tacrolimus. 2012 Transplantation pmid:23128975
First MR Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population. 2001 Transplantation pmid:11585240
Koomans HA and Ligtenberg G Mechanisms and consequences of arterial hypertension after renal transplantation. 2001 Transplantation pmid:11585243
Tarumi K et al. CTLA4IgG treatment induces long-term acceptance of rat small bowel allografts. 1999 Transplantation pmid:10071020
Trimarchi HM et al. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. 1999 Transplantation pmid:10071024
Pirsch JD et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9112351
Sokal EM et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. 1997 Transplantation pmid:9392308
McDiarmid SV et al. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. 1993 Transplantation pmid:7692636
Tabasco-Minguillan J et al. Insulin requirements after liver transplantation and FK-506 immunosuppression. 1993 Transplantation pmid:7692637
Wang SC et al. A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. 1993 Transplantation pmid:7692640
Königsrainer A et al. Nonocclusive segmental mesenteric ischemia after combined pancreas kidney transplantation: mycophenolate mofetil as an etiological factor? 2000 Transplantation pmid:10972233
Luan FL et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. 2002 Transplantation pmid:12042641
Heilman RL et al. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. 2011 Transplantation pmid:21775930
Kihm LP et al. Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography. 2012 Transplantation pmid:22470107
Saliba F et al. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study. 2016 Transplantation pmid:27454919
Jevnikar A et al. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure. 2008 Transplantation pmid:18852662
Yamazaki S et al. Transplantation-related thrombotic microangiopathy triggered by preemptive therapy for hepatitis C virus infection. 2008 Transplantation pmid:18852671
Kiuchi T CNIs: immediate benefits but storing problems for the future? 2008 Transplantation pmid:18946338
Arzouk N et al. Interaction between tacrolimus and fumagillin in two kidney transplant recipients. 2006 Transplantation pmid:16421493
Lang T et al. Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. 1996 Transplantation pmid:8824477
Andoh TF et al. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. 1994 Transplantation pmid:7509514
Eckhoff DE et al. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. 1998 Transplantation pmid:9458011
Roth D et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. 1998 Transplantation pmid:9458023
Hadley S et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. 1995 Transplantation pmid:7535482
Hooper DK et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. 2012 Transplantation pmid:22491658
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. 2008 Transplantation pmid:18622280
Bolin P et al. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results. 2008 Transplantation pmid:18622283
Miyazawa H et al. Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. 1995 Transplantation pmid:7537396
Irish W et al. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. 2003 Transplantation pmid:14688516
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Akst LM et al. Induction of tolerance in a rat model of laryngeal transplantation. 2003 Transplantation pmid:14688529
Pacifico L et al. Tacrolimus and food allergy. 2003 Transplantation pmid:14688538
Chisholm MA et al. Coadministration of tacrolimus with anti-acid drugs. 2003 Transplantation pmid:12973105
Koch R et al. Cyclosporine A-induced achalasia-like esophageal motility disorder in a liver transplant recipient: successful conversion to tacrolimus. 2003 Transplantation pmid:12973123
Dean PG et al. Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. 2008 Transplantation pmid:18431244
Shoji T et al. Operational tolerance to class I disparate lungs can be induced despite pretransplant immunization with class I allopeptides. 2007 Transplantation pmid:18091523
Richards KR et al. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. 2014 Transplantation pmid:24784360
McDiarmid SV et al. Factors affecting growth after pediatric liver transplantation. 1999 Transplantation pmid:10030286
Shapiro R et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. 1999 Transplantation pmid:10030287
Paty BW et al. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. 2002 Transplantation pmid:11884930
Florescu DF et al. Adenovirus infections in pediatric small bowel transplant recipients. 2010 Transplantation pmid:20467354
Dell'Antonio G and Randhawa PS "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. 1999 Transplantation pmid:10030300
Jun KR et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. 2009 Transplantation pmid:19384171
Ericzon BG et al. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. 1997 Transplantation pmid:9000664
Kelly PA et al. Ciprofloxacin does not block the antiproliferative effect of tacrolimus. 1997 Transplantation pmid:9000686
Ueda M et al. A proposal of FK506 optimal dosing in living related liver transplantations. 1995 Transplantation pmid:7544035
Taylor-Fishwick DA et al. Evidence that rapamycin has differential effects of IL-4 function. Multiple IL-4 signaling pathways and implications for in vivo use. 1993 Transplantation pmid:7689258
Shaefer MS et al. Falsely elevated FK-506 levels caused by sampling through central venous catheters. 1993 Transplantation pmid:7689264
Fisher A et al. FK506 hepatotoxicity in liver allograft recipients. 1995 Transplantation pmid:7539961
Valdivia LA et al. Dendritic cell replacement in long-surviving liver and cardiac xenografts. 1993 Transplantation pmid:7689265
Mikhalski D et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. 2008 Transplantation pmid:18401260
Marin-Casino M et al. Significant tacrolimus and dronedarone interaction in a kidney transplant recipient. 2014 Transplantation pmid:25243519
MacDonald A Improving tolerability of immunosuppressive regimens. 2001 Transplantation pmid:11833142
Molleví DG et al. Heart and liver xenotransplantation under low-dose tacrolimus: graft survival after withdrawal of immunosuppression. 2001 Transplantation pmid:11213062
Paolillo JA et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. 2001 Transplantation pmid:11213069
Pascual J et al. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. 2010 Transplantation pmid:20335831
Raggi MC et al. Customized mycophenolate dosing based on measuring inosine-monophosphate dehydrogenase activity significantly improves patients' outcomes after renal transplantation. 2010 Transplantation pmid:21076373
Sahara H et al. Beneficial effects of perioperative low-dose inhaled carbon monoxide on pulmonary allograft survival in MHC-inbred CLAWN miniature swine. 2010 Transplantation pmid:21076382
Min SI et al. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. 2010 Transplantation pmid:21076384
Schvarcz R et al. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). 2000 Transplantation pmid:10852623
Hewitt CW and Black KS Comparative studies of FK506 with cyclosporine. 1988 Transplantation pmid:2458644
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Ellis D et al. Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. 1991 Transplantation pmid:1714643
Mathew A et al. Reversal of steroid-resistant rejection in renal allograft recipients using FK506. 1995 Transplantation pmid:7482730
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Lerut J et al. Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. 2005 Transplantation pmid:16314784
Gruessner RW et al. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. 2008 Transplantation pmid:18192910
Komori K et al. The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. 2008 Transplantation pmid:18192920
Fuchinoue S et al. Kidney transplantation after liver transplantation from the same donor: four cases of successful steroid withdrawal. 2002 Transplantation pmid:11923698
Lauzurica R et al. Tacrolimus-associated severe bilateral corneal ulcer after renal transplantation. 2002 Transplantation pmid:11923710
Gruber SA and Doshi MD Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. 2010 Transplantation pmid:20440195
Vacher-Coponat H et al. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. 2012 Transplantation pmid:22228415
Zhang W et al. Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. 2017 Transplantation pmid:28885495
Mayer AD et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. 1997 Transplantation pmid:9275110
Guitard J et al. Predictive factors for anemia six and twelve months after orthotopic liver transplantation. 2006 Transplantation pmid:16770241